Parkinson's drug leukine passes early safety check in tiny study
NCT ID NCT03790670
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested whether a drug called Leukine (sargramostim) is safe for people with Parkinson's disease when taken for 36 months. Seven participants received a weight-based dose 5 days a week. Researchers monitored side effects, immune system changes, and motor symptoms. The goal was to see if the drug could be tolerated long-term and improve immune function linked to Parkinson's.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States